US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Valion Bio Inc

2.19

-0.1900-7.98%

Pre-market: 2.06-0.1297-5.92%06:21 EDT

Volume:129.17K

Turnover:291.82K

Market Cap:2.82M

PE:-0.01

High:2.38

Open:2.31

Low:2.18

Close:2.38

52wk High:78.75

52wk Low:2.05

Shares:1.29M

Float Shares:1.28M

Volume Ratio:0.01

T/O Rate:10.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-210.1984

EPS(LYR):-192.0762

ROE:-459.52%

ROA:-57.13%

PB:0.66

PE(LYR):-0.01

Loading ...

Overview Company News Filings

Valion Bio Sells 50 Series B Preferred Shares in $50,000 Private Placement with 3i LP

Valion Bio - May Offer up to $100 Mln of Securities - SEC Filing

THOMSON REUTERS

Valion Bio outlines perspectives of new Board Chair Jensen

Valion Bio Names Thomas Jensen Board Chair

Valion Bio, Shear Kershman formulate oral mucosal entolimod

Valion Bio, Shear Kershman Complete Oral Mucosal Entolimod Formulation Milestone

Valion Bio appoints Dean Zikria as interim CEO, Thomas Jensen as chair

Valion Bio - Appoints Dean Zikria as Interim CEO Effective September 22, 2026 - SEC Filing

THOMSON REUTERS

Valion Bio Names Dean Zikria Interim CEO

Valion Bio regains compliance with Nasdaq minimum bid price listing rule

Valion Bio Regains NASDAQ Compliance with $1 Minimum Bid Price Rule

Valion Bio Files Initial Beneficial Ownership Statement for Director Thomas Jensen

Valion Bio Inc: Lisa Wolf Appointed as President & Chief Operating Officer; to Continue to Serve as CFO

THOMSON REUTERS

Valion Bio Names CFO Lisa Wolf President, COO After CEO Handley Exits

Valion Bio Inc trading halted, news pending

Valion Bio - 1-for-25 Reverse Stock Split, Become Effective on August 31 - SEC Filing

THOMSON REUTERS

Valion Bio Announces 1-for-25 Reverse Stock Split Effective Aug. 31

Valion Bio Amends 8-K to Report Final Vote Tally on Reverse Stock Split Approval

Valion Bio Agrees to Sell 1,500 Series B Preferred Shares to 3i for $1.5 Million in Private Placement

Valion Bio - Michael K. Handley Terminated as Chief Executive Officer, Effective August 16 - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/VBIO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VBIO\",,,,,undefined,":{"symbol":"VBIO","market":"US","secType":"STK","nameCN":"Valion Bio Inc","latestPrice":2.19,"timestamp":1791403200000,"preClose":2.38,"halted":0,"volume":129166,"hourTrading":{"tag":"盘前","latestPrice":2.0603,"preClose":2.19,"latestTime":"06:21 EDT","volume":1753,"amount":3742.8096146000003,"timestamp":1791454868454,"change":-0.1297,"changeRate":-0.059224,"amplitude":0.050137},"delay":0,"changeRate":-0.07983193277310922,"floatShares":1277600,"shares":1285600,"eps":-210.1984,"marketStatus":"Pre-Mkt","change":-0.19,"latestTime":"10-08 06:40:07 EDT","open":2.31,"high":2.38,"low":2.18,"amount":291815.44384799997,"amplitude":0.084034,"askPrice":2.35,"askSize":100,"bidPrice":1.93,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-210.1984,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791466200000},"marketStatusCode":1,"adr":0,"listingDate":1636606800000,"exchange":"NASDAQ","adjPreClose":2.19,"preHourTrading":{"tag":"盘前","latestPrice":2.0603,"preClose":2.19,"latestTime":"06:21 EDT","volume":1753,"amount":3742.8096146000003,"timestamp":1791454868454,"change":-0.1297,"changeRate":-0.059224,"amplitude":0.050137},"postHourTrading":{"tag":"盘后","latestPrice":2.15,"preClose":2.19,"latestTime":"19:58 EDT","volume":4574,"amount":10002.5817,"timestamp":1791417515506,"change":-0.04,"changeRate":-0.018265,"amplitude":0.045662},"volumeRatio":0.01203696888744967},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VBIO\",,,,,undefined,":{"symbol":"VBIO","floatShares":1277600,"roa":"-57.13%","roe":"-459.52%","lyrEps":-192.076175,"volumeRatio":0.01203696888744967,"shares":1285600,"dividePrice":0,"high":2.38,"amplitude":0.084034,"preClose":2.38,"low":2.18,"week52Low":2.05,"pbRate":"0.66","psRate":"-32.74","week52High":78.75,"institutionHeld":0,"latestPrice":2.19,"eps":-210.1984,"divideRate":0,"volume":129166,"delay":0,"ttmEps":-210.1984,"open":2.31,"prevYearClose":36.25,"prevWeekClose":2.59,"prevMonthClose":2.8,"prevQuarterClose":2.8,"fiveDayClose":2.8,"twentyDayClose":2.4,"sixtyDayClose":11.73},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-31","symbol":"VBIO","defaultRemindTime":1788183000000,"type":"split","dateTimestamp":1788148800000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VBIO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VBIO","date":"2026-10-07","current":-0.010419,"percent":0.697248,"low":-0.392475,"twenty":-0.185231,"median":-0.127555,"eighty":-0.083766,"high":-0.027033,"avg":-0.14581,"sd":0.07996,"marketCap":2112461},"quantilePoints":[{"date":"2026-04-30","current":-0.311197,"twenty":-0.324163,"median":-0.319301,"eighty":-0.314439,"marketCap":2762808},{"date":"2026-05-08","current":-0.33713,"twenty":-0.336482,"median":-0.327405,"eighty":-0.314439,"marketCap":2993043},{"date":"2026-05-15","current":-0.329149,"twenty":-0.341701,"median":-0.33551,"eighty":-0.327405,"marketCap":2922183},{"date":"2026-05-22","current":-0.203146,"twenty":-0.339301,"median":-0.327405,"eighty":-0.203206,"marketCap":2758322},{"date":"2026-05-29","current":-0.18116,"twenty":-0.338751,"median":-0.311197,"eighty":-0.201597,"marketCap":2459794},{"date":"2026-06-05","current":-0.173392,"twenty":-0.33713,"median":-0.203331,"eighty":-0.18116,"marketCap":2354321},{"date":"2026-06-12","current":-0.138668,"twenty":-0.333889,"median":-0.20236,"eighty":-0.175704,"marketCap":1882829},{"date":"2026-06-18","current":-0.131547,"twenty":-0.330097,"median":-0.198754,"eighty":-0.158647,"marketCap":1786145},{"date":"2026-06-26","current":-0.136114,"twenty":-0.327754,"median":-0.18598,"eighty":-0.135201,"marketCap":1848155},{"date":"2026-07-02","current":-0.122229,"twenty":-0.327405,"median":-0.179125,"eighty":-0.130362,"marketCap":1659627},{"date":"2026-07-10","current":-0.117868,"twenty":-0.31768,"median":-0.175704,"eighty":-0.126637,"marketCap":1600412},{"date":"2026-07-17","current":-0.115133,"twenty":-0.303417,"median":-0.165705,"eighty":-0.121795,"marketCap":1563282},{"date":"2026-07-24","current":-0.06742,"twenty":-0.241361,"median":-0.149117,"eighty":-0.119839,"marketCap":915435},{"date":"2026-07-31","current":-0.065535,"twenty":-0.203355,"median":-0.136114,"eighty":-0.117713,"marketCap":889829},{"date":"2026-08-07","current":-0.064804,"twenty":-0.203188,"median":-0.130843,"eighty":-0.108033,"marketCap":879906},{"date":"2026-08-14","current":-0.040264,"twenty":-0.202832,"median":-0.129351,"eighty":-0.073786,"marketCap":546700},{"date":"2026-08-21","current":-0.027033,"twenty":-0.202055,"median":-0.126472,"eighty":-0.068316,"marketCap":506868},{"date":"2026-08-28","current":-0.145091,"twenty":-0.20046,"median":-0.129351,"eighty":-0.070603,"marketCap":2720462},{"date":"2026-09-04","current":-0.132547,"twenty":-0.198079,"median":-0.130843,"eighty":-0.073078,"marketCap":2485249},{"date":"2026-09-11","current":-0.104144,"twenty":-0.196943,"median":-0.130244,"eighty":-0.073125,"marketCap":1952695},{"date":"2026-09-18","current":-0.105564,"twenty":-0.194796,"median":-0.129235,"eighty":-0.07355,"marketCap":1979323},{"date":"2026-09-25","current":-0.164736,"twenty":-0.188071,"median":-0.128265,"eighty":-0.075261,"marketCap":3088809},{"date":"2026-10-02","current":-0.118819,"twenty":-0.187068,"median":-0.129233,"eighty":-0.079693,"marketCap":2227848},{"date":"2026-10-07","current":-0.112665,"twenty":-0.185231,"median":-0.127555,"eighty":-0.083766,"marketCap":2112461}],"updateTime":1791456007604},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VBIO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673075823","title":"Valion Bio Sells 50 Series B Preferred Shares in $50,000 Private Placement with 3i LP","url":"https://stock-news.laohu8.com/highlight/detail?id=2673075823","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673075823?lang=en_us&edition=fundamental","pubTime":"2026-10-08 18:05","pubTimestamp":1791453903,"startTime":"0","endTime":"0","summary":"Valion Bio sells 50 Series B preferred shares in $50,000 private placement with 3i LPValion Bio entered a private placement with 3i, LP for 50 Series B Non-Voting Convertible Preferred shares.Deal also includes Series B Warrants for 1,539 common shares at an initial exercise price of 2.5520 per share.Aggregate purchase price totals 50,000, subject to closing conditions in a side letter dated Oct. 7, 2026.Securities were issued in an unregistered sale under Securities Act Section 4 and/or Rule 506.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchang","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL2KGZcM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673098073","title":"Valion Bio - May Offer up to $100 Mln of Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673098073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673098073?lang=en_us&edition=fundamental","pubTime":"2026-10-08 18:03","pubTimestamp":1791453794,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T27O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673070177","title":"Valion Bio outlines perspectives of new Board Chair Jensen","url":"https://stock-news.laohu8.com/highlight/detail?id=2673070177","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673070177?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:45","pubTimestamp":1791204357,"startTime":"0","endTime":"0","summary":"Valion Bio (VBIO) outlined the perspectives of its new Board Chair, Thomas Jensen, on advancing Entolimod. Entolimod is an investigational Toll-lik...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/valion-bio-outlines-perspectives-of-new-board-chair-jensen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/valion-bio-outlines-perspectives-of-new-board-chair-jensen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VBIO","BK4139","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673870790","title":"Valion Bio Names Thomas Jensen Board Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2673870790","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673870790?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:40","pubTimestamp":1791204026,"startTime":"0","endTime":"0","summary":"Valion Bio names Thomas Jensen board chairValion Bio named Thomas H. Jensen as board chair to steer development of Entolimod for acute radiation syndrome.Jensen is CEO and a director of Nasdaq-listed ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDLbd8hyF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ALLR","VBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671019302","title":"Valion Bio, Shear Kershman formulate oral mucosal entolimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2671019302","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671019302?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:55","pubTimestamp":1790769334,"startTime":"0","endTime":"0","summary":"Valion Bio (VBIO) and Shear Kershman Laboratories announced the completion of formulation work under the companies’ ongoing program to develop a no...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/valion-bio-shear-kershman-formulate-oral-mucosal-entolimod-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/valion-bio-shear-kershman-formulate-oral-mucosal-entolimod-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4139","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671209410","title":"Valion Bio, Shear Kershman Complete Oral Mucosal Entolimod Formulation Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2671209410","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671209410?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:45","pubTimestamp":1790768738,"startTime":"0","endTime":"0","summary":"Valion Bio, Shear Kershman complete oral mucosal Entolimod formulation milestoneValion Bio reported successful formulation of an oral mucosal Entolimod using Shear Kershman’s BioViscid drug-delivery p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL6YN4jt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669485224","title":"Valion Bio appoints Dean Zikria as interim CEO, Thomas Jensen as chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2669485224","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669485224?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:26","pubTimestamp":1790166377,"startTime":"0","endTime":"0","summary":"Valion Bio (VBIO) announced decisive changes to its executive leadership team and Board of Directors. These leadership transitions are intended to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/valion-bio-appoints-dean-zikria-as-interim-ceo-thomas-jensen-as-chair-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/valion-bio-appoints-dean-zikria-as-interim-ceo-thomas-jensen-as-chair-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483405","title":"Valion Bio - Appoints Dean Zikria as Interim CEO Effective September 22, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483405","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483405?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:05","pubTimestamp":1790165112,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0MS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4139","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483180","title":"Valion Bio Names Dean Zikria Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483180","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483180?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:00","pubTimestamp":1790164859,"startTime":"0","endTime":"0","summary":"Valion Bio names Dean Zikria interim CEOValion Bio named board member Dean Zikria interim CEO to steer strategy, including Entolimod development and partnership efforts.Zikria previously held strategy","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDLYPfmS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4139","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669424931","title":"Valion Bio regains compliance with Nasdaq minimum bid price listing rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2669424931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669424931?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:55","pubTimestamp":1790081710,"startTime":"0","endTime":"0","summary":"Valion Bio (VBIO) has received formal written notification from The Nasdaq Stock Market confirming that the Company has regained compliance with th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/valion-bio-regains-compliance-with-nasdaq-minimum-bid-price-listing-rule-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/valion-bio-regains-compliance-with-nasdaq-minimum-bid-price-listing-rule-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","VBIO","BK4139","LCLG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669013141","title":"Valion Bio Regains NASDAQ Compliance with $1 Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2669013141","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669013141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:11","pubTimestamp":1790079084,"startTime":"0","endTime":"0","summary":"Valion Bio regains Nasdaq compliance with $1 minimum bid price ruleValion Bio regained compliance with Nasdaq’s $1 minimum bid price rule under Listing Rule 5550(a)(2).Nasdaq notified the company that","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL6r0dnL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668992606","title":"Valion Bio Files Initial Beneficial Ownership Statement for Director Thomas Jensen","url":"https://stock-news.laohu8.com/highlight/detail?id=2668992606","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668992606?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:31","pubTimestamp":1789677107,"startTime":"0","endTime":"0","summary":"Valion Bio files initial beneficial ownership statement for director Thomas JensenValion Bio director Thomas Jensen filed an initial SEC Form 3 on Aug. 27, 2026.Disclaimer:This news brief was created ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDLNP1K2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885672","title":"Valion Bio Inc: Lisa Wolf Appointed as President & Chief Operating Officer; to Continue to Serve as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885672","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664885672?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:08","pubTimestamp":1788264539,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0HN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VBIO","BK4082","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664300038","title":"Valion Bio Names CFO Lisa Wolf President, COO After CEO Handley Exits","url":"https://stock-news.laohu8.com/highlight/detail?id=2664300038","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664300038?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:09","pubTimestamp":1788257356,"startTime":"0","endTime":"0","summary":"Valion Bio names CFO Lisa Wolf president, COO after CEO Handley exitsValion Bio appointed CFO Lisa Wolf as president and COO, taking executive leadership following former CEO Michael K. Handley’s depa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDLbpTSS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663871019","title":"Valion Bio Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2663871019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663871019?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:50","pubTimestamp":1787961014,"startTime":"0","endTime":"0","summary":"19:50 EDT Valion Bio (VBIO) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/valion-bio-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/valion-bio-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","VBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707915","title":"Valion Bio - 1-for-25 Reverse Stock Split, Become Effective on August 31 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707915","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707915?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:33","pubTimestamp":1787833989,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O0YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","VBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707666","title":"Valion Bio Announces 1-for-25 Reverse Stock Split Effective Aug. 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707666","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707666?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833845,"startTime":"0","endTime":"0","summary":"Valion Bio announces 1-for-25 reverse stock split effective Aug. 31Valion Bio set a 1-for-25 reverse stock split, effective Aug. 31 at 12:01 a.m. ET.Shares expected to trade split-adjusted at the open","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL9z6cwd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4139","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661232321","title":"Valion Bio Amends 8-K to Report Final Vote Tally on Reverse Stock Split Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2661232321","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661232321?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:16","pubTimestamp":1787256978,"startTime":"0","endTime":"0","summary":"Valion Bio amends 8-K to report final vote tally on reverse stock split approvalValion Bio filed an amended 8-K to replace preliminary vote tallies with final results from its Aug. 14, 2026 special me","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL6tdpH8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481304","title":"Valion Bio Agrees to Sell 1,500 Series B Preferred Shares to 3i for $1.5 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481304","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660481304?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:26","pubTimestamp":1786962407,"startTime":"0","endTime":"0","summary":"Valion Bio agrees to sell 1,500 Series B preferred shares to 3i for $1.5 million in private placementValion Bio entered a $1.5 million private placement with 3i, LP, issuing 1,500 Series B Non-Voting ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL2xxr71:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4082","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660489791","title":"Valion Bio - Michael K. Handley Terminated as Chief Executive Officer, Effective August 16 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2660489791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660489791?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:12","pubTimestamp":1786961545,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nFWN44E0GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4139","VBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}]}}